The InsidesTM Company is the world’s leading provider of an award winning, therapeutic chyme reinfusion solution for the management of enterocutaneous fistula.
Enable Enterocutaneous Fistula patients to restart oral nutrition and wean off total parenteral nutrition (TPN) in 20 days, thereby allowing them to return home
(Thibault & Picot, 2016)1
- The Insides Company Receives ISO13485 Certification and CE Mark Approval for its Chyme Reinfusion Medical Devices - Press Release Source: The Insides Company Ltd On: 12:00PM, 31st January 2020 The Insides Company has received ISO13485 certification… Continue Reading
- The Insides Company rebranded from Surgical Design Studio - Press Release Source: The Insides Company Ltd On: 12:00 PM, 13th December 2019 Companies: The Insides Company, Surgical Design Studio… Continue Reading
- The remarkable Kiwi surgeon who’s helped hundreds in Nepal - This story was originally published on Newsroom.co.nz and is republished with permission. Eloise Gibson is Newsroom's environment and science editor. She's written… Continue Reading
Granted by the United States Food and Drug Administration (FDA)
Received the New Zealand Stock Exchange (NZX) Early Stage Companies Award in the 2019 TIN Report
People’s Choice for Best Project Award
Awarded the Innovative Research and Development Grant
Treating chyme as waste impedes the journey to recovery.
Chyme contains important nutrients and fluids that are lost when a patient with a loop ileostomy or enterocutaneous fistula empties their bag. This can result in complications such as:
Increased risk of Clostridium difficile
Missed or reduced chemotherapy doses
Patients who lose large volumes of chyme may require parenteral nutrition to maintain hydration and replace electrolytes. However, this is expensive and introduces new risks, including line sepsis, vascular damage and liver diseases.
Chyme reinfusion is the new standard.
Using The InsidesTM Systemfi to return chyme via the distal stoma restores the patient’s natural bowel continuity.
This can improve:
Studies have shown that restoring bowel continuity in patients on parenteral nutrition allowed them to return to an oral diet.